Diastolic blood pressure · adult participants
3 findings from 1 review
Heart rate · adult participants
3 findings from 1 review
Systolic blood pressure · adult participants
1 finding from 1 review
Diastolic blood pressure · adult participants
1 finding from 1 review
Heart rate · adult participants
1 finding from 1 review
Diastolic blood pressure · adult participants
3 findings from 1 review
Heart rate · adult participants
3 findings from 1 review
Total mortality Mean duration of 3.8 years · adults 60 years or older with primary hypertension
Antihypertensive drug leads to lower total mortality Mean duration of 3.8 years compared with placebo or no treatment (high certainty).
1 finding from 1 review
Cardiovascular mortality and morbidity Mean duration of 3.7 years · adults 60 years or older with primary hypertension
Antihypertensive drug probably leads to lower cardiovascular mortality and morbidity Mean duration of 3.7 years compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Cerebrovascular mortality + morbidity · adults 60 years or older with primary hypertension
Antihypertensive drug probably leads to lower cerebrovascular mortality and morbidity Mean duration of 3.7 years compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Coronary heart disease mortality + morbidity · adults 60 years or older with primary hypertension
Antihypertensive drug probably leads to lower coronary heart disease mortality and morbidity Mean duration of 2.9… compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults 60 years or older with primary hypertension
Antihypertensive drug may leads to higher withdrawals due to adverse effects Mean duration of 4.6 years compared with placebo or no treatment (low certainty).
1 finding from 1 review
Total mortality · adults with primary hypertension
1 finding from 1 review
Withdrawals due to adverse events · adults with primary hypertension
1 finding from 1 review
Total mortality · adults with primary hypertension
First‐line beta‐blocker showed no clear difference in total mortality compared with placebo (moderate certainty).
1 finding from 1 review
Stroke · adults with primary hypertension
First‐line beta‐blocker may leads to lower total stroke compared with placebo (low certainty).
1 finding from 1 review
Total coronary heart disease · adults with primary hypertension
First‐line beta‐blocker showed no clear difference in total coronary heart disease compared with placebo (low certainty).
1 finding from 1 review
Cardiovascular events · adults with primary hypertension
First‐line beta‐blocker may leads to lower total cardiovascular events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with primary hypertension
First‐line beta‐blocker may leads to higher withdrawal due to adverse effects compared with placebo (low certainty).
1 finding from 1 review
Total mortality · adults with primary hypertension
First‐line angiotensin converting enzyme inhibitor probably leads to lower total mortality compared with placebo (moderate certainty).
1 finding from 1 review